• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24114 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2003     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Prospective study into the influence of high-dose chemotherapy with adjuvant treatment with peripheral stem cells on the disease-free survival of patients with mammary carcinoma and four or more metastatic lymph glands in the armpit - primary research
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Prostacyclins (epoprostenol, iloprost, treprostinil and beraprost) for the management of primary pulmonary hypertension and pulmonary hypertension in collagen vascular disease
2009     Institute for Clinical Effectiveness and Health Policy (IECS) Prostacyclins (epoprostenol, iloprost, treprostinil and beraprost) for the management of primary pulmonary hypertension and pulmonary hypertension in collagen vascular disease
2007     Canadian Agency for Drugs and Technologies in Health (CADTH) Prostaglandin analogues for ophthalmic use: analysis of clinical and cost-effectiveness
2001     HAYES, Inc. Prostascint
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Prostate artery embolisation for benign prostatic hyperplasia
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Prostate artery embolisation for benign prostatic hyperplasia
2018     National Institute for Health and Care Excellence (NICE) Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 611
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Prostate artery embolisation: poor design and reporting impact the value of current systematic reviews
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia
2006     NIHR Horizon Scanning Centre (NIHR HSC) Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer: horizon scanning technology briefing
2017     Health Quality Ontario (HQO) Prostate cancer patient perspectives on the use of information in treatment decision-making: a systematic review and qualitative meta-synthesis
2011     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Prostate cancer screening
1996     Australian Health Technology Advisory Committee (AHTAC) Prostate cancer screening (consumer statement)
1996     Australian Health Technology Advisory Committee (AHTAC) Prostate cancer screening (executive summary)
1996     Australian Health Technology Advisory Committee (AHTAC) Prostate cancer screening (technical report)
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Prostate cancer screening: a review of the guidelines
1999     Basque Office for Health Technology Assessment (OSTEBA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project)
2004     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Prostate Oncoguide
2010     HAYES, Inc. Prostate Px (Aureon Laboratories Inc.) for prediction of recurrence of prostate cancer
2006     HAYES, Inc. Prostate saturation biopsy for diagnosis of prostate cancer
2005     Medical Services Advisory Committee (MSAC) Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer
1995     Health Services Utilization and Research Commission (HSURC) Prostate specific antigen (PSA) testing
2003     NIHR Health Technology Assessment programme Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
1999     NIHR Health Technology Assessment programme Prostate trials office (PROTO): co-ordinating trials of new technologies in the treatment of BPH
2009     NIHR Health Technology Assessment programme Prostate trials office (PROTO): co-ordinating trials of new technologies in the treatment of BPH
2002     Institute for Clinical Evaluative Sciences (ICES) Prostate-specific antigen (PSA) screening in asymptomatic men
2015     Health Quality Ontario (HQO) Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis
2015     Health Quality Ontario (HQO) Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis
2002     HAYES, Inc. Prostate-specific antigen testing for prognosis and monitoring of patients with prostate cancer
2003     HAYES, Inc. Prostate-specific antigen testing for screening and early detection of prostate cancer
2006     Belgian Health Care Knowledge Centre (KCE) Prostate-specific-antigen (PSA) for the screening of prostate cancer
2021     Ontario Health Prostatic artery embolization for benign prostatic hyperplasia
1992     Danish Institute for Health Services Research (DSI) Prostatic cancer in the Nordic Countries
2022     National Institute for Health and Care Excellence (NICE) Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 737
2008     Agenzia nazionale per i servizi sanitari regionali (Agenas) Prostheses for primary total hip replacement in Italy
2009     Agenzia nazionale per i servizi sanitari regionali (Agenas) Prostheses for primary total knee replacement in Italy
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Prosthetic arthroplasty in primary shoulder osteoarthritis
1994     University HealthSystem Consortium (UHC) Prosthetic hip and knee arthroplasty
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Prosthetic intervertebral disc replacement
2010     National Institute for Health and Care Excellence (NICE) Prosthetic intervertebral disc replacement in the cervical spine. NICE interventional procedures guidance 341
2009     National Institute for Health and Care Excellence (NICE) Prosthetic intervertebral disc replacement in the lumbar spine. NICE interventional procedures guidance 306
2010     The Swedish Council on Health Technology Assessment (SBU) Prosthetic rehabilitation of partially dentate or edentulous patients
2013     NIHR Horizon Scanning Centre (NIHR HSC) PROSTVAC Immunotherapy for chemotherapy-naïve hormone-relapsed prostate cancer
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Protease inhibitor use for chronic hepatitis C infection in prior null responders and recurrent hepatitis C infection post liver transplant: a review of the clinical evidence
2012     Canadian Agency for Drugs and Technologies in Health (CADTH) Protease inhibitor use for chronic hepatitis C infection in special populations: a review of the clinical evidence and guidelines
1996     Health Council of the Netherlands Gezondheidsraad (GR) Protection against diphtheria
1996     Health Council of the Netherlands Gezondheidsraad (GR) Protection against Hepatitis B
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Protein testing in patients with multiple myeloma: a review of clinical effectiveness and guidelines
2008     HAYES, Inc. Prothrombin G20210A for risk assessment for venous thromboembolism (VTE) or obstetric complications
2025     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of immunisation against respiratory syncytial virus in Ireland
2024     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of screening for abdominal aortic aneurysm in men
2025     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of teledermatology to support the management of primary care referrals
2025     NIHR Health Technology Assessment programme Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis
2008     Quality Improvement Scotland (NHS QIS ) Protocol for systematic review on provision of patient information
2025     Health Information and Quality Authority (HIQA) Protocol: development of a tool for the collection of costs attributable to infectious disease outbreaks in public acute hospitals
2015     NIHR Health Technology Assessment programme Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock
2019     NIHR Health Technology Assessment programme Protocolised non-invasive compared with invasive weaning from mechanical ventilation for adults in intensive care: the Breathe RCT
2017     Penn Medicine Center for Evidence-based Practice (CEP) Protocols for discontinuing the use of 1:1 patient sitters in the acute care setting
2005     Institute of Health Economics (IHE) Protocols for stillbirth investigation
2005     Alberta Heritage Foundation for Medical Research (AHFMR) Protocols for stillbirth investigation
2020     Austrian Institute for Health Technology Assessment (AIHTA) Proton and carbon ion therapy - an update on indications
1998     ECRI Proton beam radiation therapy for prostate cancer
2004     HAYES, Inc. Proton beam therapy
2014     Institute for Clinical and Economic Review (ICER) Proton beam therapy
2010     VA Technology Assessment Program (VATAP) Proton beam therapy for cancer
2021     Ontario Health Proton Beam Therapy for Cancer in Children and Adults: A Health Technology Assessment
2017     HAYES, Inc. Proton beam therapy for non-small cell lung cancer
2010     Blue Cross Blue Shield Association (BCBS) Proton beam therapy for non-small-cell lung cancer
2004     HAYES, Inc. Proton beam therapy for ocular tumors, hemangiomas, and macular degeneration
2006     HAYES, Inc. Proton beam therapy for prostate cancer
2010     Blue Cross Blue Shield Association (BCBS) Proton beam therapy for prostate cancer
2004     HAYES, Inc. Proton beam therapy for prostate cancer
2016     HAYES, Inc. Proton beam therapy for prostate cancer
2006     Adelaide Health Technology Assessment (AHTA) Proton Beam Therapy for the treatment of cancer
2021     Malaysian Health Technology Assessment (MaHTAS) Proton beam therapy for the treatment of cancer - an update
2017     Canadian Agency for Drugs and Technologies in Health (CADTH) Proton beam therapy for the treatment of cancer in children and adults: a health technology assessment
2007     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Proton beam therapy for the treatment of neoplasms involving (or adjacent to) cranial structures
2007     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Proton beam therapy for the treatment of uveal melanoma
2006     HAYES, Inc. Proton beam therapy for thoracic and abdominal organs
2019     Belgian Health Care Knowledge Centre (KCE) Proton beam therapy in adults
2008     HAYES, Inc. Proton magnetic resonance spectroscopy for diagnosis of brain tumors
2001     University HealthSystem Consortium (UHC) Proton pump inhibitors update
2002     Centre for Clinical Effectiveness (CCE) Proton pump inhibitors versus H2 antagonists or placebo in treating bleeding peptic ulcer
2009     Health Council of the Netherlands Gezondheidsraad (GR) Proton radiotherapy
2002     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Protontherapy (2 vols)
2013     NIHR Horizon Scanning Centre (NIHR HSC) ProUroScan™ for imaging abnormalities of the prostate
2011     HAYES, Inc. Provenge (Dendreon Corp.) vaccine for treatment of prostate cancer
2012     HAYES, Inc. Provent sleep apnea therapy (Ventus Medical Inc.)
2013     HAYES, Inc. Provent sleep apnea therapy (Ventus Medical Inc.) for obstructive sleep apnea
2011     HAYES, Inc. Provent sleep apnea therapy (Ventus Medical Inc.) for obstructive sleep apnea
2007     Center for Medical Technology Assessment (CMT) Provider payment systems in the health care sector
2005     Health Council of the Netherlands Gezondheidsraad (GR) Providing information on significant developments in health care; identification of new and changing health technology
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Providing rehabilitation services for seven days versus five days per week: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Providing rehabilitation services for seven days versus five days per week: clinical effectiveness and guidelines
2017     NIHR Health Technology Assessment programme Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project
2017     NIHR Health Technology Assessment programme Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project
2009     Quality Improvement Scotland (NHS QIS ) Provision of information to patients with long term conditions
2001     Medical Services Advisory Committee (MSAC) Provision of pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension
2004     NIHR Health Technology Assessment programme Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups